反应性神经刺激治疗超难治性局灶性癫痫持续状态:系统综述与病例系列
该系统综述与10例病例系列评估了在超难治性癫痫持续状态(SRSE)急性期植入并激活反应性神经刺激(RNS)系统的安全性和有效性。10例均为局灶性癫痫持续状态(9例SRSE,1例难治性癫痫持续状态),7例在RNS植入激活后1至27天脱离SRSE,2例死于持续SRSE并发症,1例出现无需干预的设备相关显著不良事件(微量出血)。作者认为RNS对符合入选标准、有1-2个明确癫痫发作起始区的SRSE患者可能是安全且潜在有效的治疗选择,需进一步研究最佳刺激参数。
要点
- 10例局灶性癫痫持续状态患者中,7例在RNS植入激活后1至27天脱离SRSE。
- 2例死于持续SRSE并发症,1例出现无需干预的设备相关显著不良事件(微量出血)。
- 作者认为RNS对符合入选标准且有1-2个明确发作起始区的SRSE患者可能是安全且潜在有效的选择。
核心结论
- 该病例系列提供初步证据表明,RNS对符合RNS入选标准、有1-2个明确癫痫发作起始区的SRSE患者可能是安全且潜在有效的治疗选择。
- RNS的独特特性在SRSE场景中提供多种益处,包括实时皮层脑电图补充头皮脑电图以监测SRSE进展和治疗反应,以及多种刺激选项。
- 作者指出需进一步研究该独特临床场景下的最佳刺激参数。
研究设计与样本
- 系统文献综述结合10例病例系列,检索数据库和美国癫痫学会摘要(最后检索日期为2023年3月1日)并直接联系RNS系统制造商。
- 共识别10例在癫痫持续状态急性期使用RNS的病例(9例SRSE和1例难治性癫痫持续状态[RSE])。
- 9个中心获得IRB批准进行回顾性病历审查并填写数据收集表,第10例引用已发表的病例报告数据。
- 数据收集表与已发表病例报告的数据汇总于Excel。
主要发现
- 10例均表现为局灶性癫痫持续状态:9例SRSE和1例RSE。
- 病因包括已知病变(7例局灶性皮质发育不良和1例复发性脑膜瘤)和未知病因(2例,其中1例表现为新发难治性局灶性癫痫持续状态[NORSE])。
- 10例中7例在RNS植入并激活后脱离SRSE,时间范围为1至27天。
- 2例患者死于持续SRSE导致的并发症;另1例患者的癫痫持续状态从未缓解但为亚临床。
- 10例中1例出现设备相关显著不良事件(微量出血),无需干预;在SRSE缓解的病例中,至定义终点报告1例出院后癫痫持续状态复发。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Super-refractory status epilepticus (SRSE) has high rates of morbidity and mortality. Few published studies have investigated neurostimulation treatment options in the setting of SRSE. This systematic literature review and series of 10 cases investigated the safety and efficacy of implanting and activating the responsive neurostimulation (RNS) system acutely during SRSE and discusses the rationale for lead placement and selection of stimulation parameters. METHODS: Through a literature search (of databases and American Epilepsy Society abstracts that were last searched on March 1, 2023) and direct contact with the manufacturer of the RNS system, 10 total cases were identified that utilized RNS acutely during SE (9 SRSE cases and 1 case of refractory SE [RSE]). Nine centers obtained IRB approval for retrospective chart review and completed data collection forms. A tenth case had published data from a case report that were referenced in this study. Data from the collection forms and the published case report were compiled in Excel. RESULTS: All 10 cases presented with focal SE: 9 with SRSE and 1 with RSE. Etiology varied from known lesion (focal cortical dysplasia in 7 cases and recurrent meningioma in 1) to unknown (2 cases, with 1 presenting with new-onset refractory focal SE [NORSE]). Seven of 10 cases exited SRSE after RNS placement and activation, with a time frame ranging from 1 to 27 days. Two patients died of complications due to ongoing SRSE. Another patient's SE never resolved but was subclinical. One of 10 cases had a device-related significant adverse event (trace hemorrhage), which did not require intervention. There was 1 reported recurrence of SE after discharge among the cases in which SRSE resolved up to the defined endpoint. CONCLUSIONS: This case series offers preliminary evidence that RNS is a safe and potentially effective treatment option for SRSE in patients with 1-2 well-defined seizure-onset zone(s) who meet the eligibility criteria for RNS. The unique features of RNS offer multiple benefits in the SRSE setting, including real-time electrocorticography to supplement scalp EEG for monitoring SRSE progress and response to treatment, as well as numerous stimulation options. Further research is indicated to investigate the optimal stimulation settings in this unique clinical scenario.
引用
- Ernst LD, Raslan AM, Wabulya A, et al. Responsive neurostimulation as a treatment for super-refractory focal status epilepticus: a systematic review and case series. J Neurosurg. 2023. PMID: 37329518. doi:10.3171/2023.4.JNS23367
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。